Previous Close | 37.00 |
Open | 36.97 |
Bid | 36.96 x 48300 |
Ask | 36.97 x 51100 |
Day's Range | 36.58 - 36.99 |
52 Week Range | 33.75 - 44.81 |
Volume | |
Avg. Volume | 626,755 |
Market Cap | 8.181B |
Beta (5Y Monthly) | 0.42 |
PE Ratio (TTM) | 25.67 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 1.18 (2.94%) |
Ex-Dividend Date | Jan 30, 2024 |
1y Target Est | N/A |
QIAGEN's (QGEN) new products, coupled with the IVD version of QIAGEN's digital PCR platform QIAcuity, are planned to be released in mid-2024.
With QIAGEN's (QGEN) QIAstat-Dx Analyzer 2.0's integration of remote access, central and regional laboratories may work together efficiently, particularly when it comes to decentralized testing.
QIAGEN's (QGEN) collaboration with IPPA follows the updated CDC guidelines for TB screening for immigrants in the United States.